Please assess the completion status of the following clinical trial:

Trial Title: Neuropathic Pain Syndrome Patient Study (MK-0000-072)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has moderate to severe nerve pain due to one of the following conditions: Postherpetic neuralgia, Painful diabetic neuropathy, Small fiber neuropathy or idiopathic distal sensory polyneuropathy~* Patient is able to complete questionnaires in either English or Spanish~* Patient is at least 18 years of age~Exclusion Criteria:~* Patient is either pregnant or breastfeeding~* Patient has a history of angioedema (swelling beneath the skin surface) or peripheral edema (foot, leg, and/or ankle swelling)~* Patient has a history of congestive heart failure~* Patient has a seizure disorder~* Patient has a history of drug and/or alcohol abuse within the past 1 year~* Patient failed treatment due to lack of pain relief with more than three drugs for nerve pain~* Patient has had cancer (except basal cell carcinoma) within the past two years~* Patient anticipates the need for surgery while participating in the study~* Patient has a reported history of hepatitis B, C, or HIV infection~* Patient has another type of pain that is more painful than the nerve pain~* Patient has generalized anxiety disorder, untreated depression, psychosis, or post-traumatic stress disorder~* Patient is involved in litigation or receives worker's compensation related to nerve pain

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Patients in Group A will remain on pregabalin (up to 600 mg/day po) treatment for the entire double-blind period.
- B (Type: PLACEBO_COMPARATOR): Patients in Group B will be treated with placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).